Compounds > vasopressin, 1-deamino-4-val-8-arg-
Page last updated: 2024-12-11

vasopressin, 1-deamino-4-val-8-arg-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

vasopressin, 1-deamino-4-Val-8-Arg-: highly potent & specific antidiuretic possessing protracted effects; RN given refers to (L-Val-L-Arg)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44419026
CHEMBL ID435323
MeSH IDM0050280
PubMed CID6441676
MeSH IDM0050280

Synonyms (21)

Synonym
dvdavp
CHEMBL435323 ,
bdbm50205304
val4-ddavp
[deamino-cys1, val4, d-arg8]-vasopressin
43157-23-9
1-[(4r,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-10-(propan-2-yl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl]-l-prolyl-n~5~-(diaminomethylidene)-d-ornithylglycinamide
DTXSID90658832
(deamino-cys1,val4,d-arg8)-vasopressin
[deamino-cys1, val4, d-arg8]-vasopressin, >=95%
mfcd00080166
(2s)-n-[(2r)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4r,7s,10s,13s,16s)-7-(2-amino-2-oxoethyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-10-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-
CS-0635196
HY-P4008
[deamino-4-valine, 8-d-arginine]-vasopressin
vasopressin 1-(3-mercaptopropanoic acid)-4-l-valine-8-l-arginine-
51980-16-6
1-deamino-4-valyl-8-arginine vasopressin
vasopressin, 1-deamino-4-valyl-8-arginine-
vasopressin, 1-deamino-4-val-8-arg-
(1-deamino,4-valine)-8-d-argininevasopressin

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The duration of the action of sublingually administered DDAVP was 12 hrs; after dosing DVDAVP the effect lasted even 6 hrs."( Effects of vasopressin analogues (DDAVP, DVDAVP) in the form of sublingual tablets in central diabetes insipidus.
Julesz, J; Laczi, F; Lázló, FA; Mezei, G, 1981)		0.26
" [4-Threonine, 7-glycine]oxytocin, a highly potent and selective uterotonic oxytocin analogue, had no detectable prostaglandin-releasing activity at a dosage 30 times higher than oxytocin."( Agonist and antagonist specificities of decidual prostaglandin-releasing oxytocin receptors and myometrial uterotonic oxytocin receptors in pregnant rats.
Chan, WY; Chen, DL; Manning, M, 1994)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Translocator proteinMus musculus (house mouse)Ki0.00030.00030.00030.0004AID277899
Vasopressin V2 receptor Rattus norvegicus (Norway rat)Ki0.00030.00030.97919.7000AID277899
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Vasopressin V2 receptorHomo sapiens (human)EC50 (µMol)0.00000.00000.55066.7000AID1598498
Oxytocin receptorHomo sapiens (human)EC50 (µMol)0.35000.00000.08050.8810AID1598499
Vasopressin V1b receptorHomo sapiens (human)EC50 (µMol)0.02400.00000.03600.2400AID1598501
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (54)

Processvia Protein(s)Taxonomy
positive regulation of systemic arterial blood pressureVasopressin V2 receptorHomo sapiens (human)
renal water retentionVasopressin V2 receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
activation of adenylate cyclase activityVasopressin V2 receptorHomo sapiens (human)
hemostasisVasopressin V2 receptorHomo sapiens (human)
positive regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
negative regulation of cell population proliferationVasopressin V2 receptorHomo sapiens (human)
positive regulation of gene expressionVasopressin V2 receptorHomo sapiens (human)
telencephalon developmentVasopressin V2 receptorHomo sapiens (human)
response to cytokineVasopressin V2 receptorHomo sapiens (human)
positive regulation of intracellular signal transductionVasopressin V2 receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V2 receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V2 receptorHomo sapiens (human)
suckling behaviorOxytocin receptorHomo sapiens (human)
response to amphetamineOxytocin receptorHomo sapiens (human)
muscle contractionOxytocin receptorHomo sapiens (human)
cell surface receptor signaling pathwayOxytocin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationOxytocin receptorHomo sapiens (human)
heart developmentOxytocin receptorHomo sapiens (human)
lactationOxytocin receptorHomo sapiens (human)
memoryOxytocin receptorHomo sapiens (human)
response to xenobiotic stimulusOxytocin receptorHomo sapiens (human)
positive regulation of norepinephrine secretionOxytocin receptorHomo sapiens (human)
telencephalon developmentOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicOxytocin receptorHomo sapiens (human)
response to estradiolOxytocin receptorHomo sapiens (human)
response to progesteroneOxytocin receptorHomo sapiens (human)
response to anoxiaOxytocin receptorHomo sapiens (human)
response to cytokineOxytocin receptorHomo sapiens (human)
social behaviorOxytocin receptorHomo sapiens (human)
response to cocaineOxytocin receptorHomo sapiens (human)
maternal behaviorOxytocin receptorHomo sapiens (human)
sperm ejaculationOxytocin receptorHomo sapiens (human)
eating behaviorOxytocin receptorHomo sapiens (human)
response to peptide hormoneOxytocin receptorHomo sapiens (human)
estrous cycleOxytocin receptorHomo sapiens (human)
positive regulation of blood pressureOxytocin receptorHomo sapiens (human)
digestive tract developmentOxytocin receptorHomo sapiens (human)
positive regulation of synapse assemblyOxytocin receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicOxytocin receptorHomo sapiens (human)
positive regulation of penile erectionOxytocin receptorHomo sapiens (human)
ERK1 and ERK2 cascadeOxytocin receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionOxytocin receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisOxytocin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayOxytocin receptorHomo sapiens (human)
female pregnancyOxytocin receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinOxytocin receptorHomo sapiens (human)
positive regulation of vasoconstrictionOxytocin receptorHomo sapiens (human)
maternal process involved in parturitionOxytocin receptorHomo sapiens (human)
cellular response to hormone stimulusOxytocin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayVasopressin V1b receptorHomo sapiens (human)
activation of phospholipase C activityVasopressin V1b receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVasopressin V1b receptorHomo sapiens (human)
positive regulation of phospholipase A2 activityVasopressin V1b receptorHomo sapiens (human)
regulation of cell population proliferationVasopressin V1b receptorHomo sapiens (human)
positive regulation of MAPK cascadeVasopressin V1b receptorHomo sapiens (human)
symbiont entry into host cellVasopressin V1b receptorHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processVasopressin V1b receptorHomo sapiens (human)
positive regulation of arachidonic acid secretionVasopressin V1b receptorHomo sapiens (human)
transport across blood-brain barrierVasopressin V1b receptorHomo sapiens (human)
cellular response to hormone stimulusVasopressin V1b receptorHomo sapiens (human)
regulation of systemic arterial blood pressure by vasopressinVasopressin V1b receptorHomo sapiens (human)
positive regulation of vasoconstrictionVasopressin V1b receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
vasopressin receptor activityVasopressin V2 receptorHomo sapiens (human)
protein bindingVasopressin V2 receptorHomo sapiens (human)
peptide bindingVasopressin V2 receptorHomo sapiens (human)
peptide hormone bindingOxytocin receptorHomo sapiens (human)
peptide bindingOxytocin receptorHomo sapiens (human)
vasopressin receptor activityOxytocin receptorHomo sapiens (human)
oxytocin receptor activityOxytocin receptorHomo sapiens (human)
vasopressin receptor activityVasopressin V1b receptorHomo sapiens (human)
protein kinase C bindingVasopressin V1b receptorHomo sapiens (human)
peptide bindingVasopressin V1b receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
endosomeVasopressin V2 receptorHomo sapiens (human)
endoplasmic reticulumVasopressin V2 receptorHomo sapiens (human)
Golgi apparatusVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
membraneVasopressin V2 receptorHomo sapiens (human)
endocytic vesicleVasopressin V2 receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneVasopressin V2 receptorHomo sapiens (human)
perinuclear region of cytoplasmVasopressin V2 receptorHomo sapiens (human)
plasma membraneVasopressin V2 receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
microvillusOxytocin receptorHomo sapiens (human)
adherens junctionOxytocin receptorHomo sapiens (human)
apical plasma membraneOxytocin receptorHomo sapiens (human)
plasma membraneOxytocin receptorHomo sapiens (human)
endosomeVasopressin V1b receptorHomo sapiens (human)
Golgi apparatusVasopressin V1b receptorHomo sapiens (human)
plasma membraneVasopressin V1b receptorHomo sapiens (human)
plasma membraneVasopressin V1b receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (44)

Assay IDTitleYearJournalArticle
AID1148688Antidiuretic activity in iv dosed rat1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Design of potent antagonists of the vasopressor response to arginine-vasopressin.
AID277896Vasopressor activity in rat2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID1598498Agonist activity at recombinant human V2 receptor expressed in HEK293 cells measured after 5 hrs by cAMP response element driven luciferase reporter gene assay
AID1150192Ratio of arginine-vasopressin to compound for antidiuretic activity in sc dosed Brattleboro rat hereditary hypothalamic diabetes insipidus model1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-deaminopenicillamine,4-valine]-8-D-arginine-vasopressin, a highly potent inhibitor of the vasopressor response to arginine-vasopressin.
AID1150141Ratio of antidiuretic activity in Brattleboro rat to vasopressor activity in rat1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
AID1150133Oxytocic activity in rat uterus in presence of Mg2+1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
AID1150135Vasopressor activity in rat1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
AID1150893Activity at oxytocin receptor in rat uterus1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
AID1598501Agonist activity at recombinant human V1B receptor expressed in HEK293 cells measured after 5 hrs by luciferase reporter gene assay
AID277900Displacement of [3H]AVP from vasopressin V1a receptor in rat liver membrane2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID1598506Clearance in Sprague-Dawley rat at 0.1 mg/kg, iv administered as cassette dose by LC-MS/MS analysis
AID1150187Antidiuretic activity in sc dosed Brattleboro rat hereditary hypothalamic diabetes insipidus model measured over 6 hrs1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-deaminopenicillamine,4-valine]-8-D-arginine-vasopressin, a highly potent inhibitor of the vasopressor response to arginine-vasopressin.
AID1150894Activity at oxytocin receptor in rat uterus in presence of Mg2+1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
AID1598499Agonist activity at human OTR stably expressed in CHOK1 cells by NFAT-luciferase reporter gene assay
AID197144Tested for intravenous anti-oxytocic effect in the absence of Mg2+ in rats; agonist at concentration of 8 units/kg1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
[1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to argi
AID1598529Antidiuretic activity in iv dosed rat assessed as suppression of urine output relative to control
AID230908Ratio of antidiuretic to vasopressor agonistic activity; Infinite1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.
AID168452Compound was tested for its antidiuretic activity1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.
AID1150140Antidiuretic activity in sc dosed Brattleboro rat assessed as spontaneous urine output measured every 1 hr for 24 hrs1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
AID172987Tested for intravenous antidiuretic activity in rats1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
[1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to argi
AID1150897Ratio of antidiuretic activity in rat to vasopressor activity in rat1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
AID1148687Antivasopressor activity in iv dosed phenoxybenzamine treated rat assessed as inhibition of arginine-vasopressin-induced effect1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Design of potent antagonists of the vasopressor response to arginine-vasopressin.
AID197146Tested for intravenous anti-vasopressor pA2 effect in rats1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
[1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to argi
AID173420Dose that reduces the response seen with 2x units of agonist to equal the response seen with 1x unit of agonist administered before antagonist1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.
AID1150184Oxytocic activity in Sherman albino rat uterus assessed as contraction1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-deaminopenicillamine,4-valine]-8-D-arginine-vasopressin, a highly potent inhibitor of the vasopressor response to arginine-vasopressin.
AID1150895Antidiuretic activity in rat1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
AID1598508Protein binding in rat plasma at 200 to 1000 ng/ml measured after 15 mins by UC-LC/MS/MS analysis
AID277895Antidiuretic activity in rat2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID196969In vitro anti-oxytocic activity on isolated estrogen treated rat uteri without Mg+2; Agonist1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.
AID1598505Agonist activity at recombinant human V1a receptor expressed in HEK293 cells up to 1000 nM measured after 5 hrs by luciferase reporter gene assay
AID1132554Antidiuretic activity in iv dosed rat assessed as agonist activity on arginine-vasopressin-induced effect1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
[1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),4-valine,-8-D-arginine]vasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin.
AID1132555Antivasopressor activity in iv dosed phenoxybenzamine treated rat assessed as antagonist activity on arginine-vasopressin-induced effect1978Journal of medicinal chemistry, Mar, Volume: 21, Issue:3
[1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),4-valine,-8-D-arginine]vasopressin, a potent and selective inhibitor of the vasopressor response to arginine-vasopressin.
AID277899Displacement of [3H]AVP from vasopressin V2 receptor in rat kidney membranes2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
AID196847In vitro anti-oxytocic activity on isolated estrogen treated rat uteri with 0.5 mM Mg+2; Agonist1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.
AID196810Binding affinity was determined1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
2-O-alkyltyrosine derivatives of 1-deamino-arginine-vasopressin: highly specific and potent antidiuretic agonists.
AID1598503Selectivity ratio of EC50 for human OTR stably expressed in CHOK1 cells to EC50 for recombinant human V2 receptor expressed in HEK293 cells
AID1598500Agonist activity at human OTR stably expressed in CHOK1 cells by NFAT-luciferase reporter gene assay relative to control
AID1150189Antivasopressor activity in iv dosed phenoxybenzamine-treated rat assessed as inhibition of arginine-vasopressin-induced vasopressor response1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-deaminopenicillamine,4-valine]-8-D-arginine-vasopressin, a highly potent inhibitor of the vasopressor response to arginine-vasopressin.
AID1150132Oxytocic activity in rat uterus in absence of Mg2+1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
[1-(L-2-hydroxy-3-mercaptopropanoic acid)] analogues of arginine-vasopressin, [8-D-arginine]vasopressin, and [4-valine,8-D-arginine]vasopressin.
AID1598504Selectivity ratio of EC50 for recombinant human V1B receptor expressed in HEK293 cells to EC50 for recombinant human V2 receptor expressed in HEK293 cells
AID1598502Agonist activity at recombinant human V1B receptor expressed in HEK293 cells measured after 5 hrs by luciferase reporter gene assay relative to control
AID1150896Vasopressor activity in rat1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
AID1598507Non-renal clearance in nephrectomized Sprague-Dawley rat at 0.1 mg/kg, iv administered as cassette dose by LC-MS/MS analysis
AID277897Activity at OT receptor assessed as oxytocic activity in absence of magnesium2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (56.25)18.7374
1990's12 (37.50)18.2507
2000's1 (3.13)29.6817
2010's1 (3.13)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.25 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.47 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
argipressin, val(4)-
argipressin, Val(4)-: RN given refers to (L-Val-D-Arg)-isomer		1.9510
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		1.9510heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
lypressin
Lypressin: The porcine antidiuretic hormone (VASOPRESSINS). It is a cyclic nonapeptide that differs from ARG-VASOPRESSIN by one amino acid, containing a LYSINE at residue 8 instead of an ARGININE. Lys-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.		1.9510cyclic peptide
arginine vasopressin
Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.		3.0650vasopressincardiovascular drug;
hematologic agent;
mitogen
deamino arginine vasopressin
Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.		2.6730heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(o- methyl-l-tyrosine)-8-l-arginine-
vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-: highly potent antagonist of vasopressor response to arginine-vasopressin; structure in first source		1.9510
deaminooxytocin
deaminooxytocin: octa-peptide lacking free amino group on cystine residue; RN given refers to cpd without isomeric designation		1.9510
aldosterone
[no description available]		1.981011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		2.8740L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		1.9510arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
vasotocin
Vasotocin: A nonapeptide that contains the ring of OXYTOCIN and the side chain of ARG-VASOPRESSIN with the latter determining the specific recognition of hormone receptors. Vasotocin is the non-mammalian vasopressin-like hormone or antidiuretic hormone regulating water and salt metabolism.. vasotocin : A heterodetic cyclic peptide that is homologous to oxytocin and vasopressin. It is a pituitary hormone that acts as an endocrine regulator for water balance, osmotic homoeostasis and is involved in social and sexual behavior in non-mammalian vertebrates.		2.3920
1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(o-ethyl-tyr)-4-val-arginine vasopressin
1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-2-(O-ethyl-Tyr)-4-Val-arginine vasopressin: RN refers to (L-Tyr-L-Val-L-Arg)-isomer ; vasopressin antagonist		2.3720
argipressin,beta-mercapto-beta,beta-cyclopentamethylenepropionic acid(1)-val(4)-
argipressin,beta-mercapto-beta,beta-cyclopentamethylenepropionic acid(1)-Val(4)-: potent, selective inhibitor of vasopressor response to arginine vasopressin		1.9610
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		1.9810amino acid zwitterion;
angiotensin II		human metabolite
argipressin, beta-mercapto-beta,beta-cyclopentamethylenepropionic acid(1)-ile(2)-abu(4)-
argipressin, beta-mercapto-beta,beta-cyclopentamethylenepropionic acid(1)-Ile(2)-Abu(4)-: an arginine vasopressin (AVP) V2 receptor antagonist		1.9810
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		3.4880heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
lypressin
Lypressin: The porcine antidiuretic hormone (VASOPRESSINS). It is a cyclic nonapeptide that differs from ARG-VASOPRESSIN by one amino acid, containing a LYSINE at residue 8 instead of an ARGININE. Lys-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.		2.3720cyclic peptide
arginine vasopressin
Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.		4.17170vasopressincardiovascular drug;
hematologic agent;
mitogen
argipressin, deaminopenicillamine(1)-val(4)-
argipressin, deaminopenicillamine(1)-Val(4)-: antagonist of vasopressor effect of vasopressin		2.3820
oxytocin, phe(2)-orn(8)-
oxytocin, Phe(2)-Orn(8)-: RN given refers to all (L)-isomer		2.8940
dinoprost
Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.		1.9810monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
alprostadil
[no description available]		1.9810prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
deamino arginine vasopressin
Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.		4.45230heterodetic cyclic peptidediagnostic agent;
renal agent;
vasopressin receptor agonist
vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(o- methyl-l-tyrosine)-8-l-arginine-
vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-: highly potent antagonist of vasopressor response to arginine-vasopressin; structure in first source		3.0750
isotocin
isotocin: hormone found in some teleosts; Gln in position 4 of oxytocin replaced by Ser & Leu in position 8 by Ile; structure		1.9910
pituitrin
Pituitrin: A substance or extract from the neurohypophysis (PITUITARY GLAND, POSTERIOR).		3.4780
beta-endorphin
beta-Endorphin: A 31-amino acid peptide that is the C-terminal fragment of BETA-LIPOTROPIN. It acts on OPIOID RECEPTORS and is an analgesic. Its first four amino acids at the N-terminal are identical to the tetrapeptide sequence of METHIONINE ENKEPHALIN and LEUCINE ENKEPHALIN.. beta-endorphin : A polypeptide consisting of 31 amino acid residues in the sequence Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu. It is an endogenous opioid peptide neurotransmitter found in the neurons of both the central and peripheral nervous system and results from processing of the precursor protein proopiomelanocortin (POMC).		1.9610
ConditionIndicatedRelationship StrengthStudiesTrials
Water Intoxication
A condition resulting from the excessive retention of water with sodium depletion.		01.9610
Diabetes Insipidus
A disease that is characterized by frequent urination, excretion of large amounts of dilute URINE, and excessive THIRST. Etiologies of diabetes insipidus include deficiency of antidiuretic hormone (also known as ADH or VASOPRESSIN) secreted by the NEUROHYPOPHYSIS, impaired KIDNEY response to ADH, and impaired hypothalamic regulation of thirst.		02.8740
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		01.9610
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.3820
Blood Pressure, High
[description not available]		02.3820
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		02.3820
Pyrexia
[description not available]		01.9810
Fever
An abnormal elevation of body temperature, usually as a result of a pathologic process.		01.9810
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		01.9710
Autosomal Hemophilia A
[description not available]		01.9610
Angiohemophilia
[description not available]		01.9610
Hemophilia A
The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage.		01.9610
von Willebrand Diseases
Group of hemorrhagic disorders in which the VON WILLEBRAND FACTOR is either quantitatively or qualitatively abnormal. They are usually inherited as an autosomal dominant trait though rare kindreds are autosomal recessive. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII, and impaired platelet adhesion.		01.9610
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9510